Endonovo Therapeutics Inc (ENDV)

[davidsson10]

Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.

March 25, 2020 08:00 ET | Source: Endonovo Therapeutics, Inc.


Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse® investigational units to Hospital Intensive Care Units across the United States to help mitigate severe respiratory inflammation observed in some COVID-19 patients.

Through Endonovo's Chief Medical Officer and consulting with our Scientific Advisory Board, we have identified a pathway for SofPulse® for the reduction of severe respiratory inflammation symptoms related to COVID-19. SofPulse® Pulsed Electromagnetic Fields Therapy (PEMF) device is FDA-cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue. Medical researchers previously working with SofPulse® in trials and clinical studies have identified an anti-inflammatory response through which SofPulse® PEMF technology may help mitigate the severe respiratory inflammation observed in some COVID-19 patients.

Endonovo CEO, Alan Collier comments, “We have requested FDA emergency clearance for SofPulse® devices to be used for the treatment for severe respiratory inflammatory complications for COVID-19 patients. We believe SofPulse® PEMF technology may help to mitigate the severe respiratory inflammation observed in some COVID-19 patients much like it does in post-operative wounds, reducing morbidity and mortality and yielding faster recovery.”

Endonovo is currently donating 50 investigational units to hospital Intensive Care Units treating COVID-19 patients suffering from lung inflammation symptoms. With COVID-19 being classified as a worldwide Pandemic, the Company is hopeful patients affected by this virus may be able to benefit from SofPulse® PEMF technology.

COVID-19 causes a release of pro-inflammatory cytokines, which contribute to overwhelming inflammation termed a "cytokine storm” in the respiratory system leading to worsened clinical outcomes. Clinical studies show, SofPulse® has an anti-inflammatory effect at the cellular level with no known side effects. SofPulse® has shown to reduce IL-1 Beta by 275% at the 18-hour mark after surgery. The mechanism of action is noninvasive reduction of pro-inflammatory cytokine IL-1 Beta and improvement of circulation in tissues. This inflammatory reduction is the same response that has been implicated in the heightened inflammatory response resulting from the COVID-19 infection leading to increases in morbidity and mortality rates. (https://lnkd.in/gNJ7Q38)

Our company believes SofPulse® may help to reduce inflammatory symptoms of COVID-19 patients. SofPulse's® anti-inflammatory effect may reduce the need for ventilators and improve recovery times in some COVID-19 patients.

For additional information regarding SofPulse® donations, please email Endonovo at [e-mail] with any questions or requests - or contact Endonovo directly at 800.701.1223 x110.